Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-06
DOI
10.1038/s41419-019-2210-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
- (2019) Rashmi R. Shah DRUG SAFETY
- Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy
- (2019) Qing Li et al. Immunotherapy
- Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy
- (2018) Pei-Guo Wang et al. JOURNAL OF NEURO-ONCOLOGY
- The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat
- (2017) Chiara Zagni et al. MEDICINAL RESEARCH REVIEWS
- Chidamide in the treatment of peripheral T-cell lymphoma
- (2017) Thomas Chan et al. OncoTargets and Therapy
- The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo
- (2017) Annarita Scialdone et al. Oncotarget
- Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
- (2016) Grzegorz S. Nowakowski et al. JNCI-Journal of the National Cancer Institute
- Activation of integrin α5 mediated by flow requires its translocation to membrane lipid rafts in vascular endothelial cells
- (2016) Xiaoli Sun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Diffuse large B-cell lymphoma: R-CHOP failure--what to do?
- (2016) B. Coiffier et al. Hematology-American Society of Hematology Education Program
- Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
- (2016) Grzegorz S. Nowakowski et al. JNCI-Journal of the National Cancer Institute
- A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
- (2015) R. Chen et al. HAEMATOLOGICA
- Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
- (2015) Jagannath Behera et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
- (2015) R. Chen et al. HAEMATOLOGICA
- Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia
- (2014) L. Jia et al. BLOOD
- Postulated Mechanisms of Resistance of B-Cell Non-Hodgkin Lymphoma to Rituximab Treatment Regimens: Strategies to Overcome Resistance
- (2014) Benjamin Bonavida SEMINARS IN ONCOLOGY
- Interaction of membrane/lipid rafts with the cytoskeleton: Impact on signaling and function
- (2013) Brian P. Head et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
- (2013) Bjoern Chapuy et al. CANCER CELL
- Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas
- (2012) Mei Dong et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment
- (2012) Hiroaki Miyoshi et al. CANCER SCIENCE
- CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma
- (2012) Tsuyoshi Nakamaki et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of Outcome
- (2012) Paul Greaves et al. JOURNAL OF CLINICAL ONCOLOGY
- Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
- (2011) Zhi-Qiang Ning et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
- (2010) S. A. Beers et al. BLOOD
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
- (2010) R Shimizu et al. LEUKEMIA
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- A unique chromatin signature uncovers early developmental enhancers in humans
- (2010) Alvaro Rada-Iglesias et al. NATURE
- Histone H3K27ac separates active from poised enhancers and predicts developmental state
- (2010) M. P. Creyghton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
- (2009) J. Hiraga et al. BLOOD
- Phosphotyrosine protein dynamics in cell membrane rafts of sphingosine-1-phosphate-stimulated human endothelium: Role in barrier enhancement
- (2009) Jing Zhao et al. CELLULAR SIGNALLING
- Chemical mechanisms of histone lysine and arginine modifications
- (2008) Brian C. Smith et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels
- (2008) M. S. Czuczman et al. CLINICAL CANCER RESEARCH
- Origin and pathogenesis of nodular lymphocyte–predominant Hodgkin lymphoma as revealed by global gene expression analysis
- (2008) Verena Brune et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Stromal Gene Signatures in Large-B-Cell Lymphomas
- (2008) G. Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now